Despite Surmodics’ security measures, its information technology and infrastructure may be vulnerable to attacks by hackers resulting from employee error, malfeasance or other disruptions. The secure maintenance of this information is critical to its operations and business strategy, and the company’s customers expect that it will securely maintain their information. Downsidesĭata Security Threats: Surmodics collects and stores sensitive data, including intellectual property, its proprietary business information and that of its customers, suppliers and business partners, on its networks. Strong potential in the company’s Sublime Radial Access device and Pounce Arterial Thrombectomy platform raises our optimism about the stock. Surmodics confirmed making crucial progress on its SurVeil DCB pre-market approval submission. The company registered robust revenues from its IVD segment, as well as from its Product sales. Strong Q2 Results: Surmodics’ solid second-quarter fiscal 2022 results buoy optimism about the stock. Additionally, the data showed that no adjunctive thrombectomy devices were required to remove clots and 95% of these procedures could be performed while avoiding the use of thrombolytics within the target lesion. In April, Surmodics announced that its Pounce Thrombectomy System achieved 100% technical success in 20 FIH procedures. Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. launch of SurVeil will follow the receipt of the pre-market approval.
The expectation continues to be that the U.S.
During its fiscal 2022 second-quarter earnings call, Surmodics confirmed that it was anticipating that the 24-month TRANSCEND clinical data will be presented at an upcoming conference later this fall. SurVeil is a paclitaxel DCB used for the treatment of femoral-popliteal disease. It does not store any personal data.Progress With TRANSCEND: Surmodics received investigational device exemption approval from the FDA for its SurVeil drug-coated balloon (“DCB”) pivotal study named TRANSCEND. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is used to store the user consent for the cookies in the category "Other. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". Questi cookie garantiscono funzionalità di base, analisi di dati aggregati sul comportamento dell'utente e caratteristiche di sicurezza del sito web, in modo anonimo. I cookie necessari sono assolutamente essenziali per il corretto funzionamento del sito web.
0 kommentar(er)
